+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy

In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy

Molecular Cancer Research 10(3): 428-440

Aberrations in epidermal growth factor receptor (EGFR/ErbB1) are the most common oncogenic alterations in glioblastoma multiforme (GBM), the most common primary brain tumor. Interactions between wild-type (wt) and mutant EGFRs and their subsequent activation are of biologic and potential therapeutic importance in GBMs. We recently showed that in situ proximity ligation assay (PLA) allows for quantitative evaluation of EGFR dimerization and activation in intact cells. Using this in situ platform, we show the aberrant homo-/heterodimeric properties of EGFRvIII and EGFRc958 mutants, the two most common EGFR mutants in GBMs. In addition, dimer phosphoactivation status could be detected by PLA with superior signal-noise ratio (>17-fold) and sensitivity (>16-fold) than immunofluorescence-based phospho-EGFR measurements. Dimer activation analysis indicated quantitative activation differences of mutant dimers. These aberrant features were not overexpression dependent but appeared independent of cellular expression levels, suggesting inherent properties of the mutant receptors. Moreover, we observed in situ detection of EGFRwt-EGFRvIII heterodimerization in GBM specimens, supporting our cell line observations. Notably, currently used anti-EGFR therapeutics, such as cetuximab, matuzumab, and panitumumab, could effectively block EGFRwt dimerization and activation but did not equally impair EGFRvIII homodimers, EGFRwt-EGFRvIII, or EGFRvIII-EGFRc958 heterodimers. EGFRvIII appears to have intrinsic phosphoactivation independent of dimerization as matuzumab blockade of homodimerization had no effect on receptor phosphorylation levels. These data suggest differences in the dimerization-blocking efficacy of EGFR monoclonal antibodies as mutant EGFR dimer configurations prevalent in GBMs can evade blockade by anti-EGFR treatments. Further studies are warranted to evaluate whether this evasion contributes to poor therapeutic response or resistance.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053764899

Download citation: RISBibTeXText

PMID: 22232519

DOI: 10.1158/1541-7786.MCR-11-0531

Related references

Effects of a ribozyme targeted against deletion-mutant EGFR mRNA on tumorigenicity of human glioblastoma multiforme in animal system. Proceedings of the American Association for Cancer Research Annual Meeting 42: 651, 2001

MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro-Oncology 16(6): 868-879, 2015

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Molecular Cancer Therapeutics 14(2): 542-552, 2015

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. European Journal of Pharmacology 810: 70-82, 2017

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. Oncotarget 7(34): 54137-54156, 2016

In situ detection of telomeres by fluorescence in situ hybridization and telomerase activity in glioblastoma multiforme: correlation with p53 status, EGFR, c-myc, MIB1, and Topoisomerase IIalpha protein expression. International Journal of Oncology 23(6): 1529-1535, 2003

EGFR overexpression and radiation response in glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics 51(2): 410-418, October 1, 2001

Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM. Clinical Neuropathology 24(4): 163-169, 2005

Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation. Mutagenesis 29(5): 341-350, 2015

Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. Journal of Neuro-Oncology 85(1): 39-47, 2007

Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. Journal of Neuro-Oncology 123(2): 307-314, 2016

Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro-Oncology 15(4): 480-489, 2013

Does EGFR targeted therapy change the natural history of EGFR mutant status?. Journal of B.U.On. 22(2): 560-561, 2017

Our experience with targeted therapy in glioblastoma multiforme. Magyar Onkologia 57(4): 264-268, 2014

Glioblastoma multiforme targeted therapy: The Chlorotoxin story. Journal of Clinical Neuroscience 33: 52-58, 2016